TSE:IN InMed Pharmaceuticals (IN) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free IN Stock Alerts C$4.19 -0.07 (-1.64%) (As of 05/7/2021) Add Compare Share Share Today's RangeC$4.13▼C$4.2750-Day RangeC$4.19▼C$4.1952-Week RangeC$3.35▼C$13.86Volume17,035 shsAverage Volume29,552 shsMarket CapitalizationC$33.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get InMed Pharmaceuticals alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About InMed Pharmaceuticals Stock (TSE:IN)InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More IN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IN Stock News HeadlinesApril 6, 2024 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD StudiesFebruary 13, 2024 | finanznachrichten.deInMed Pharmaceuticals: InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business UpdateApril 29, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 13, 2024 | finance.yahoo.comInMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business UpdateJanuary 22, 2024 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside ChatJanuary 16, 2024 | finance.yahoo.comInMed Pharmaceuticals Provides Business Update and Milestones for 2024December 12, 2023 | finance.yahoo.comInMed’s (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer’s with a Rare Cannabinoid AnalogNovember 30, 2023 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular DegenerationApril 29, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… November 29, 2023 | finance.yahoo.comInMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular DegenerationNovember 14, 2023 | msn.comInMed Pharmaceuticals GAAP EPS of -$0.76, revenue of $901.8MOctober 24, 2023 | finance.yahoo.comInMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept StudiesOctober 13, 2023 | benzinga.comCannabis Industry Report Highlights Positive Sentiment and Growth Potential at Benzinga ConferenceAugust 11, 2023 | finanznachrichten.deDelveInsight Business Research, LLP: Epidermolysis Bullosa Market to Surge at a CAGR of ~8% During the Study Period (2019-2032), Predicts DelveInsightJuly 20, 2023 | finance.yahoo.comInMed Provides Update on BayMedica Rare Cannabinoid BusinessJuly 7, 2023 | msn.comGame-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds PromiseApril 25, 2023 | marketwatch.comBiosynthesis of Cannabinoids Market Growth By 2030April 20, 2023 | marketwatch.comBlepharitis-Pipeline Market Description and Business Overview By 2030March 27, 2023 | benzinga.comInMed Pharmaceuticals: Pushing Pharma Forward With Rare CannabinoidsMarch 17, 2023 | benzinga.comDespite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023March 13, 2023 | finance.yahoo.comInMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin ConditionsFebruary 21, 2023 | benzinga.comInMed Pharmaceuticals Q2 FY23 Revenue Grows 77% YoY, What About Net Loss?February 20, 2023 | marketwatch.comEpidermolysis Bullosa Market is Booming in Near Future 2023-2028 with Top Countries DataFebruary 20, 2023 | finanznachrichten.deInMed Pharmaceuticals Inc.: InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business UpdateFebruary 17, 2023 | yahoo.comInMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business UpdateFebruary 17, 2023 | msn.comInMed Pharmaceuticals GAAP EPS of -$0.91, revenue of $0.47MFebruary 10, 2023 | finance.yahoo.comInMed Submits Form 12b-25See More Headlines Receive IN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:IN CUSIPN/A CIKN/A Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio8.48 Current Ratio2.13 Quick Ratio1.45 Sales & Book Value Annual SalesC$574,677.00 Price / Sales58.70 Cash FlowC$0.40 per share Price / Cash Flow10.40 Book ValueC$0.76 per share Price / Book5.50Miscellaneous Outstanding Shares8,051,000Free FloatN/AMarket CapC$33.73 million OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Eric A. Adams (Age 58)Pres, CEO & Director Comp: $488.44kMs. Alexandra Diane-Janet Mancini (Age 69)Sr. VP of Clinical & Regulatory Affairs Comp: $337.13kDr. Sazzad Hossain M.Sc. (Age 64)Ph.D., Co-Founder Ms. Brenda Edwards C.M.A.CPA, Interim Chief Financial OfficerMr. Michael Woudenberg P.Eng. (Age 55)Chief Operating Officer Colin ClancySr. Director of Investor RelationsMr. Jerry P. GriffinVP of Sales & MarketingDr. Eric Chih-Hsien Hsu (Age 52)Sr. VP of Preclinical R&D Dr. Shane A. Johnson Ph.D.Sr. VP & GM of BayMedicaDr. Ado MuhammadSr. Consultant of Medical AffairsMore ExecutivesKey CompetitorsMeta GrowthCVE:METAZomedica Pharmaceuticals Corp. (ZOM.V)CVE:ZOMMediPharm LabsTSE:LABSViridium Pacific GroupCVE:VIRMedexus PharmaceuticalsTSE:MDPView All CompetitorsInsidersEric Ashley AdamsBought 41,600 shares on 2/20/2024Total: C$14,921.92 ($0.36/share) IN Stock Analysis - Frequently Asked Questions How have IN shares performed in 2024? InMed Pharmaceuticals' stock was trading at C$4.19 at the start of the year. Since then, IN shares have increased by 0.0% and is now trading at C$4.19. View the best growth stocks for 2024 here. What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include Organigram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU). How do I buy shares of InMed Pharmaceuticals? Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:IN) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
